Anti-Coagulants - Mozambique

Mozambique

In Mozambique, the Anti-Coagulants market is anticipated to achieve a revenue of US$4.24m in 2024.
Looking ahead, there is an expected annual growth rate (CAGR 2024-2029) of 9.48%, leading to a market volume of US$6.67m by 2029.
When compared globally, United States will generate the highest revenue in the market, amounting to US$16,740.00m in 2024.
The demand for anti-coagulants in Mozambique is rising due to the increasing prevalence of cardiovascular diseases in the country.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The use of Anti-Coagulants in Mozambique is on the rise, with several factors contributing to the development of the market.

Customer preferences: Patients in Mozambique are increasingly becoming aware of the benefits of Anti-Coagulants in treating and preventing blood clots. As a result, there is a growing demand for these drugs, particularly among the elderly population who are more susceptible to blood clots.

Trends in the market: One of the key trends in the Anti-Coagulants market in Mozambique is the shift towards newer oral anticoagulants (NOACs). These drugs have been shown to be more effective than traditional anticoagulants, such as warfarin, and have fewer side effects. This trend is in line with the global market, where NOACs are becoming increasingly popular.

Local special circumstances: Mozambique has a high burden of infectious diseases such as HIV/AIDS, malaria, and tuberculosis. These diseases can increase the risk of blood clots, which in turn increases the demand for Anti-Coagulants. Additionally, the country has a rapidly growing elderly population, which is expected to further drive the demand for these drugs.

Underlying macroeconomic factors: Mozambique is one of the fastest-growing economies in Africa, with a growing middle class and an expanding healthcare sector. This is expected to fuel the demand for Anti-Coagulants as more people are able to afford these drugs. However, the country still faces challenges such as a lack of healthcare infrastructure and limited access to healthcare in rural areas. This could limit the growth of the Anti-Coagulants market in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.